Boundless Bio, Inc. (BOLD) Stock
BOLD Key Statistics
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
CEO: Zachary Hornby. Company website
BOLD — Frequently Asked Questions
What is the BOLD stock price today?
Boundless Bio, Inc. (BOLD) trades at $2.60, up 85.71% on the day, as of Nov 12, 2026 10:46 UTC.
What is Boundless Bio, Inc.'s market cap?
Boundless Bio, Inc. has a market capitalisation of $58.26M, calculated from the live BOLD share price and shares outstanding.
What is the P/E ratio of BOLD?
BOLD has no meaningful price-to-earnings ratio: Boundless Bio, Inc. lost $2.61 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Boundless Bio, Inc. make?
Boundless Bio, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for BOLD?
BOLD has traded between $1.07 and $2.75 over the past 52 weeks, and the last price is 5.5% below that high.
Is Boundless Bio, Inc. profitable?
Yes. Boundless Bio, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for BOLD?
Wall Street analysts rate BOLD Hold.
What sector is Boundless Bio, Inc. in?
Boundless Bio, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Boundless Bio, Inc.?
Zachary Hornby is the chief executive of Boundless Bio, Inc., which employs 64 people.
Where can I track BOLD in real time?
QFI Terminal shows BOLD with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BOLD live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BOLD in Terminal See plans